Literature DB >> 11246561

Effect of intradermal tumor necrosis factor-alpha-induced inflammation on coagulation factors in dermal vessel endothelium. An in vivo study of human skin biopsies.

W Speiser1, S Kapiotis, C W Kopp, I Simonitsch, B Jilma, B Jansen, M Exner, A Chott.   

Abstract

Inflammatory mediators were shown to exert procoagulant effects on cultured human endothelial cells (EC). In the present study the effect of intradermal application of tumor necrosis factor-alpha (TNF-alpha) on the expression of factors involved in regulation of coagulation at the EC surface, i.e. tissue factor (TF), thrombomodulin (TM) and tissue factor pathway inhibitor (TFPI) was studied in humans in vivo. The endothelial expression of these factors was evaluated immunohistochemically in biopsies taken after intradermal application of 5000 U TNF-alpha in 8 healthy volunteers. After 6 and 22 h biopsies were taken from the injection sites. At TNF-alpha injected sites typical inflammatory changes. e.g. EC upregulation of adhesion molecules and accumulation of leukocytes were detected. In parallel we could document EC expression of TF, downregulation of TM and depletion of tissue factor pathway inhibitor (TFPI) in inflamed areas. Early depletion of endothelial IkappaB alpha at the site of inflammation after application of TNF-alpha points to an activation of the NF-kappaB pathway. Our data suggest that, as shown in in vitro experiments, TNF-alpha activates the NF-kappaB pathway and induces specific procoagulant changes of EC due to expression of TF, down-regulation of TM and depletion of TFPI in vivo in humans. This procoagulant shift in the haemostatic balance on the cell surface, caused by TNF-alpha-induced inflammation, is likely to contribute to thrombosis associated with tissue inflammation in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246561

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Genetic regulation of endothelial inflammatory responses in baboons.

Authors:  David L Rainwater; Qiang Shi; Michael C Mahaney; Vida Hodara; John L Vandeberg; Xing Li Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-27       Impact factor: 8.311

Review 2.  Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins.

Authors:  Radjesh J Bisoendial; Erik S G Stroes; John J P Kastelein; Paul Peter Tak
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

3.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state.

Authors:  Jakub Swadzba; Teresa Iwaniec; Jacek Musial
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

4.  Innate immunity genes influence the severity of acute appendicitis.

Authors:  Fernando A Rivera-Chavez; Dixie L Peters-Hybki; Robert C Barber; Guy M Lindberg; Ishwarlal Jialal; Robert S Munford; Grant E O'Keefe
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

5.  Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice.

Authors:  Katerina Akassoglou; Eleni Douni; Jan Bauer; Hans Lassmann; George Kollias; Lesley Probert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-09       Impact factor: 11.205

6.  Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells.

Authors:  Hong Jin; Wen-Bing Qiu; Yi-Fang Mei; Dong-Ming Wang; Yu-Guang Li; Xue-Rui Tan
Journal:  Asian J Androl       Date:  2009-01-26       Impact factor: 3.285

7.  PKCζ as a promising therapeutic target for TNFα-induced inflammatory disorders in chronic cutaneous wounds.

Authors:  Jian Zhang; Xuekang Yang; Hongtao Wang; Bin Zhao; Xue Wu; Linlin Su; Songtao Xie; Yunchuan Wang; Jun Li; Jiaqi Liu; Mengdong Liu; Fu Han; Ting He; Wei Zhang; Ke Tao; Dahai Hu
Journal:  Int J Mol Med       Date:  2017-09-20       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.